# MEDICAL SECTOR - CLINICAL TRIAL DATA SUMMARY

## Document ID: MED-2025-7823
## Data Classification: HIPAA PROTECTED

### Section 1: Trial Overview

Protocol SENT-2025-001: AI-Assisted Diagnostic Support Clinical Trial
Principal Investigator: Dr. Katherine Williams, MD PhD
Institution: Johns Hopkins University Medical Center
Trial Phase: Phase 2b, randomized controlled study

Enrollment statistics:
- Total enrolled patients: 847
- Active participants: 792
- Completed treatment: 412
- Withdrawn: 55 (6.5% dropout rate)

### Section 2: Efficacy Results

Primary endpoint: Diagnostic accuracy improvement vs standard of care
Results: 34% improvement in early detection of malignant lesions
Secondary endpoint: Time to diagnosis reduced from 72 hours to 18 hours average

Key findings by site:
- Site A (Dr. Michael Roberts, Boston): 38% improvement (n=312)
- Site B (Dr. Lisa Chang, Chicago): 31% improvement (n=285)
- Site C (Dr. James Patterson, Houston): 33% improvement (n=250)

### Section 3: Safety Data

Adverse events tracked by Safety Officer Dr. Sarah Thompson.
Total AE reports: 23 (2.7% of participants)
Serious AE: 2 events, both unrelated to study intervention per DSMB review.

DSMB recommendation: Continue enrollment with no protocol modifications.
FDA correspondence managed by Regulatory Affairs lead Jennifer Martinez.
